Find A Research Study
Study Name: Liver Disease Registry and Tissue Repository
Category: Gastroenterology
Currently accepting participants?
Yes - please read the description below and contact the study coordinator if you are interested.
Principal Investigator: Kris Kowdley
Study Coordinator: Cheryl Saunders
Phone: 206 341 1786 Ext.11786
Email: gascjs@vmmc.org
What is the Liver Disease Registry and Tissue Repository study?
The purpose of the Liver Disease Registry and Repository is to learn more about the causes and effects of various liver diseases and to identify and maintain a list of patients who might be interested in participating in future clinical research studies related to his or her disease.
Who can participate?
Males and females of age 18 or greater who have been diagnosed with or are suspected to have the following liver diseases: Autoimmune Hepatitis (AIH), Hepatitis B (HBV), Hepatitis C (HCV), Nonalcoholic Fatty Liver Disease (NAFLD), Iron Overload, Primary Biliary Cirrhosis (PBC), Primary Sclerosing Cholangitis (PSC), or Wilson’s Disease.
What do I have to do as a study participant?
The registry and repository is an observational study only and no treatment is involved. Participation involves the collection of health history and disease history as well as blood, urine, and/or liver tissue samples.
Other studies in this category include:
Studies currently accepting study participants:
- 5-arm, parallel-group study of the effects on viral kinetics, safety and pharmacokinetics of different dosing regimens of Debio 025 in combination with peginterferon alpha-2a and ribavirin in chronic HCV genotype 1 patients who non-responders to standard
- 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared with Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients with HBeAg Negative Chronic Hepatitis due to Hepatitis B Virus
- 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared with Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients with HBeAg Positive Chronic Hepatitis due to Hepatitis B Virus
- A Phase IIb, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of AT-1001 in Celiac Disease Subjects during a Gluten Challenge.
- A Randomized Phase II/III of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer
- Abatacept in Treatment of Patient with Active Crohns Disease (CD) who have had an Inadequate Clinical Response and/or Intolerance to Medical Therapy
- Abatacept in Treatment of Patient with Active Ulcerative Colitis (UC) who have had an Inadequate Clinical Response and/or Intolerance to Medical Therapy
- Evaluation of PillCam® ESO 2 in Patients with Suspected Esophageal Pathologies
- Liver Disease Registry and Tissue Repository
- RG1068 (Synthetic Human Secretin) – Enhanced MRCP in the Evaluation of Subjects with a History of Acute or Acute Recurrent Pancreatitis
Studies currently not accepting study participants:
No studies currently listed. Please try another category.